Pedersen E B, Kornerup H J
Eur J Clin Pharmacol. 1977 Oct 14;12(2):93-6. doi: 10.1007/BF00645128.
Plasma renin concentration (PRC) was measured in 46 patients with essential hypertension before and after treatment for 4 weeks with alprenolol 600-1200 mg daily. In 27 of these patients PRC was measured after 4 weeks of combined treatment with alprenolol and hydralizine. During alprenolol treatment PRC and blood pressure were reduced, but the changes were not correlated. Alprenolol treatment caused similar blood pressure reductions in patients with high and low PRC, and the antihypertensive efficacy of beta-adrenergic blocking agents could not be predicted from the pretreatment PRC. When beta-adrenergic blockade was supplemented with hydralazine, blood pressure was further reduced, but PRC remained unchanged. Although a causal relationship between blood pressure reduction and suppression of renin, production might exist at low doses of beta-adrenergic blocking agents, the present study did not indicate such a relationship when higher doses were used. It was shown that alprenolol inhibited the increase in PRC usually induced by hydralazine, but it is not known whether this was important for the effectiveness of the fall in blood pressure produced by hydralazine.
对46例原发性高血压患者测定了血浆肾素浓度(PRC),这些患者每日服用600 - 1200毫克阿普洛尔治疗4周前后均进行了检测。其中27例患者在阿普洛尔与肼屈嗪联合治疗4周后测定了PRC。在阿普洛尔治疗期间,PRC和血压均降低,但二者变化不相关。阿普洛尔治疗使PRC高和低的患者血压降低程度相似,且无法根据治疗前的PRC预测β - 肾上腺素能阻滞剂的降压疗效。当β - 肾上腺素能阻滞剂与肼屈嗪联合使用时,血压进一步降低,但PRC保持不变。尽管低剂量β - 肾上腺素能阻滞剂降压与肾素分泌抑制之间可能存在因果关系,但本研究在使用较高剂量时未显示出这种关系。结果表明,阿普洛尔抑制了通常由肼屈嗪诱导的PRC升高,但尚不清楚这对肼屈嗪降低血压的有效性是否重要。